Neuraminidase inhibitors--the story behind the Cochrane review
Description
Although billions have been spent on oseltamivir in the face of pandemic influenza, the team updating the Cochrane review of neuraminidase inhibitors in healthy adults found that the public evidence base for this global public health drug was fragmented and inconsistent. Peter Doshi tells the storyCitation
Doshi P. (2009). Neuraminidase inhibitors--the story behind the Cochrane review. BMJ 2009;339:b5164. DOI: https://doi.org/10.1136/bmj.b5164Keyword
neuraminidase inhibitorsTamiflu
public health policy
drug efficacy
Systematic reviews (Medical research)
Influenza, Human--drug therapy
Oseltamivir